|
|
Volumn 360, Issue 9348, 2002, Pages 1890-1891
|
|
Questions about anastrozole for early breast cancer [8] (multiple letters)
a,b
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANASTROZOLE;
AROMATASE;
AROMATASE INHIBITOR;
BIOLOGICAL MARKER;
ESTROGEN;
ESTROGEN RECEPTOR;
NEU DIFFERENTIATION FACTOR;
TAMOXIFEN;
ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;
NITRILE;
TRIAZOLE DERIVATIVE;
ADJUVANT CHEMOTHERAPY;
ANTINEOPLASTIC ACTIVITY;
BONE DENSITY;
BONE MINERAL;
BREAST CARCINOMA;
CANCER COMBINATION CHEMOTHERAPY;
CANCER HORMONE THERAPY;
CANCER RECURRENCE;
CANCER REGRESSION;
CLINICAL TRIAL;
COGNITION;
COGNITIVE DEFECT;
DRUG CONTRAINDICATION;
DRUG EFFICACY;
DRUG TOLERABILITY;
EARLY CANCER;
ENZYME INHIBITION;
FOLLOW UP;
HORMONE RESPONSE;
HUMAN;
LETTER;
LIPID ANALYSIS;
LIPID METABOLISM;
LONG TERM CARE;
LYMPH NODE METASTASIS;
MONOTHERAPY;
POSTMENOPAUSE;
PRIORITY JOURNAL;
PROTEIN DETERMINATION;
RISK BENEFIT ANALYSIS;
SIDE EFFECT;
BREAST TUMOR;
DISEASE COURSE;
FEMALE;
NOTE;
ANTINEOPLASTIC AGENTS, HORMONAL;
BREAST NEOPLASMS;
CLINICAL TRIALS;
DISEASE PROGRESSION;
FEMALE;
HUMANS;
NITRILES;
TRIAZOLES;
|
|
EID: 0037038862
PISSN: 01406736
EISSN: None
Source Type: Journal
DOI: 10.1016/s0140-6736(02)11758-2 Document Type: Letter |
|
Times cited : (1)
|
|
References (0)
|
